Anaplastic Thyroid Cancer Clinical Trial
Official title:
A Critical Analysis of Anaplastic Thyroid Clinical Trials: Perspectives From Patient Experiences
| NCT number | NCT05819593 |
| Other study ID # | 80865259 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | May 2024 |
| Est. completion date | May 2026 |
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.
| Status | Not yet recruiting |
| Enrollment | 500 |
| Est. completion date | May 2026 |
| Est. primary completion date | May 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosed with anaplastic thyroid cancer - Willing to comply with all study related procedures and assessments - Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol Exclusion Criteria: - No documented diagnosis of anaplastic thyroid cancer - Any serious and/or unstable pre-existing medical disorders - Pregnant or lactating woman |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Power Life Sciences Inc. |
Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. Cancers (Basel). 2020 Jul 29;12(8):2104. doi: 10.3390/cancers12082104. — View Citation
Ljubas J, Ovesen T, Rusan M. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer. Cancers (Basel). 2019 Jul 4;11(7):943. doi: 10.3390/cancers11070943. — View Citation
Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018 Oct 23;17(1):154. doi: 10.1186/s12943-018-0903-0. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of anaplastic thyroid cancer patients who decide to enroll in a clinical study | 3 months | ||
| Primary | Rate of anaplastic thyroid cancer patients who remain in a clinical study to completion | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04420754 -
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
|
Phase 1 | |
| Completed |
NCT02152137 -
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04552769 -
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Completed |
NCT02688608 -
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
| Terminated |
NCT00095693 -
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01240590 -
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04579757 -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06362694 -
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
|
Phase 2 | |
| Recruiting |
NCT06374602 -
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
|
Phase 2 | |
| Withdrawn |
NCT01701349 -
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03085056 -
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
|
Early Phase 1 | |
| Recruiting |
NCT01774279 -
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
|
||
| Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT02244463 -
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05696548 -
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
|
Phase 2 | |
| Terminated |
NCT00603941 -
A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel
|
Phase 1/Phase 2 | |
| Completed |
NCT00280852 -
Review of Multimodality Management of Anaplastic Thyroid Cancer
|
N/A | |
| Recruiting |
NCT04238624 -
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT06079333 -
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
|
Phase 2 |